{
    "symbol": "KPTI",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-05 21:38:05",
    "content": " The key upcoming milestones we are focused to on over the near-term, in addition to our continued focus on driving commercial performance, are to dose the first patient in our Phase III study, evaluating the all-oral SPD triplet in patients with relapse or refractory multi myeloma by the end of the first half of 2022; and receive a decision from CHMP on our application requesting approval for selinexor, rituximab and dexamethasone in patients with multiple myeloma following at least 1 prior therapy also during the first half of 2022."
}